N-(2-(sec-butyl)phenyl)acetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-(sec-butyl)phenyl)acetamide
• 英文别名: N-(2-butan-2-ylphenyl)acetamide
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: LHCWDMHDVKNVDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-(1-甲丙基)苯胺 、 乙酸酐 在 N,N,N-trimethyl-2-(sulfooxy)ethanaminium chloride 作用下， 以 neat (no solvent) 为溶剂， 反应 0.27h， 以90%的产率得到N-(2-(sec-butyl)phenyl)acetamide
  参考文献：
  名称：

  砂石法合成硫酸胆碱离子液体催化乙酰胺

  摘要：

  已发现硫酸胆碱离子液体（SCIL）是一种有效的固体酸IL催化剂，可在无溶剂磨石条件下用乙酸酐保护胺基。这种新的催化方法的吸引人的特点包括其可持续性，简便的后处理程序，经济可行性和生物降解性。使用红外光谱，广角X射线散射分析和具有能量色散X射线光谱的扫描电子显微镜对SCIL催化剂进行了表征。该催化剂可以重复使用六次，而不会显着降低活性。此外，无需色谱分离即可获得所需的产物。

  DOI：

  10.1016/j.tetlet.2017.03.023

文献信息

• Substituted pyrazoles as p38 kinase inhibitors
  申请人：Naraian S. Ashok

  公开号：US20070078146A1

  公开（公告）日：2007-04-05

  A class of pyrazole derivatives is described for use in treating p38 kinase medicated disorders. Compounds of particular interest are defined by Formula IA wherein R 1 , R 2 , R 3 and R 4 are as described in the specification.

  描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。特别感兴趣的化合物由公式IA定义，其中R1、R2、R3和R4如规范中所述。
• Inhibitors of human phosphatidylinositol 3-kinase delta
  申请人：ICOS CORPORATION

  公开号：US10010550B2

  公开（公告）日：2018-07-03

  Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.

  本发明公开了抑制磷脂酰肌醇 3- 激酶δ异构体（PI3Kδ）活性的方法，以及治疗 PI3Kδ 在白细胞功能中发挥作用的疾病（如免疫和炎症紊乱）的方法。优选地，这些方法采用的活性剂可选择性地抑制 PI3Kδ，同时不会明显抑制其他 PI3K 同工酶的活性。提供了抑制 PI3Kδ 活性的化合物，包括选择性抑制 PI3Kδ 活性的化合物。还提供了使用 PI3Kδ 抑制性化合物抑制癌细胞生长或增殖的方法。因此，本发明提供了使用 PI3Kδ 抑制性化合物抑制体外和体内 PI3Kδ 介导过程的方法。
• INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA
  申请人：ICOS CORPORATION

  公开号：US20170049772A1

  公开（公告）日：2017-02-23

  Methods of inhibiting phosphotidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating disease, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the methods employ active agents that selectively inhibit PI3Kδ, while not significantly inhibiting activity of other PI3K isoforms. Compounds are provided that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity. Methods of using PI3Kδ inhibitory compounds to inhibit cancer cell growth or proliferation are also provided. Accordingly, the invention provides methods of using PI3Kδ inhibitory compounds to inhibit PI3Kδ-mediated processes in vitro and in vivo.
• US7378426B2
  申请人：——

  公开号：US7378426B2

  公开（公告）日：2008-05-27
• Sulfated choline ionic liquid-catalyzed acetamide synthesis by grindstone method
  作者：Reddi Mohan Naidu Kalla、Jaehwa Lim、Jaeyeong Bae、Il Kim

  DOI：10.1016/j.tetlet.2017.03.023

  日期：2017.4

  Sulfated choline ionic liquid (SCIL) has been found to be an efficient solid acid IL catalyst for the protection of amine groups with acetic anhydride under solvent-free grindstone conditions. The attractive features of this new catalytic methodology include its sustainability, facile work-up procedure, economic viability, and biodegradability. The SCIL catalyst was characterized using infrared spectroscopy

  已发现硫酸胆碱离子液体（SCIL）是一种有效的固体酸IL催化剂，可在无溶剂磨石条件下用乙酸酐保护胺基。这种新的催化方法的吸引人的特点包括其可持续性，简便的后处理程序，经济可行性和生物降解性。使用红外光谱，广角X射线散射分析和具有能量色散X射线光谱的扫描电子显微镜对SCIL催化剂进行了表征。该催化剂可以重复使用六次，而不会显着降低活性。此外，无需色谱分离即可获得所需的产物。